Bipolar treatment update: Evidence is driving change in mania, depression algorithms
Current Psychiatry. 2004 February;03(02):22-45
February 1, 2004|Current Psychiatry
Author and Disclosure Information
Texas Medication Algorithm Project will weigh data on atypical antipsychotics in mania and on continuing antidepressants after bipolar depression remits.
Dr. Suppes receives research support from or is a consultant to Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Janssen Pharmaceutica, Johnson & Johnson, National Institutes of Mental Health, Novartis Pharmaceuticals Corp., Pfizer Inc., Pharmaceutical Research Institute, Ortho-McNeil Pharmaceutical, Robert Wood Johnson Pharmaceutical Research Institute, The Stanley Medical Research Institute, and UCB Pharma.
